10558-45-9Relevant articles and documents
Niclosamide quantification in methyl-β-cyclodextrin after derivatization to aminoniclosamide
Algarra, Manuel,Campos, Bruno B.,Rodriguez-Borges, Jose E.,Sanchez, Francisco G.,Lopez-Romero, Juan M.,Esteves Da Silva, Joaquim C. G.
, p. 89 - 94 (2012)
A fluorescence derivatization method for the quantification of the anthelmintic drug niclosamide in organized media (methyl-β-cyclodextrin) is described. The derivatization reaction is based on a 3 h reduction reaction of the nitro group in niclosamide to an amino group by hydrogenation catalyzed by Pd/C in methanol:ethyl acetate (1:3). The aminoniclosamide exhibits a maximum of fluorescence at 431 nm (excitation at 280 nm) that is markedly enhanced when methyl-β-cyclodextrin is present. The methodology was assessed by the analysis of pure and dosage forms. The method showed a linear range between 0 and 2200 μg L-1 with a limit of detection of 45.7 nL and a precision (relative standard deviation) of 4.1% in niclosamide. The effect of various interferents, such as niclosamide, fructose and 2-cyano-6- metoxybenzothiazole, in several tolerance ratios, was investigated respected to aminoniclosamide.
Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
Shamim, Khalida,Xu, Miao,Hu, Xin,Lee, Emily M,Lu, Xiao,Huang, Ruili,Shah, Pranav,Xu, Xin,Chen, Catherine Z.,Shen, Min,Guo, Hui,Chen, Lu,Itkin, Zina,Eastman, Richard T.,Shinn, Paul,Klumpp-Thomas, Carleen,Michael, Sam,Simeonov, Anton,Lo, Donald C.,Ming, Guo-li,Song, Hongjun,Tang, Hengli,Zheng, Wei,Huang, Wenwei
supporting information, (2021/03/30)
Zika virus has emerged as a potential threat to human health globally. A previous drug repurposing screen identified the approved anthelminthic drug niclosamide as a small molecule inhibitor of Zika virus infection. However, as antihelminthic drugs are generally designed to have low absorption when dosed orally, the very limited bioavailability of niclosamide will likely hinder its potential direct repurposing as an antiviral medication. Here, we conducted SAR studies focusing on the anilide and salicylic acid regions of niclosamide to improve physicochemical properties such as microsomal metabolic stability, permeability and solubility. We found that the 5-bromo substitution in the salicylic acid region retains potency while providing better drug-like properties. Other modifications in the anilide region with 2′-OMe and 2′-H substitutions were also advantageous. We found that the 4′-NO2 substituent can be replaced with a 4′-CN or 4′-CF3 substituents. Together, these modifications provide a basis for optimizing the structure of niclosamide to improve systemic exposure for application of niclosamide analogs as drug lead candidates for treating Zika and other viral infections. Indeed, key analogs were also able to rescue cells from the cytopathic effect of SARS-CoV-2 infection, indicating relevance for therapeutic strategies targeting the COVID-19 pandemic.
Aluminum Metal-Organic Framework-Ligated Single-Site Nickel(II)-Hydride for Heterogeneous Chemoselective Catalysis
Antil, Neha,Kumar, Ajay,Akhtar, Naved,Newar, Rajashree,Begum, Wahida,Dwivedi, Ashutosh,Manna, Kuntal
, p. 3943 - 3957 (2021/04/12)
The development of chemoselective and heterogeneous earth-abundant metal catalysts is essential for environmentally friendly chemical synthesis. We report a highly efficient, chemoselective, and reusable single-site nickel(II) hydride catalyst based on robust and porous aluminum metal-organic frameworks (MOFs) (DUT-5) for hydrogenation of nitro and nitrile compounds to the corresponding amines and hydrogenolysis of aryl ethers under mild conditions. The nickel-hydride catalyst was prepared by the metalation of aluminum hydroxide secondary building units (SBUs) of DUT-5 having the formula of Al(μ2-OH)(bpdc) (bpdc = 4,4′-biphenyldicarboxylate) with NiBr2 followed by a reaction with NaEt3BH. DUT-5-NiH has a broad substrate scope with excellent functional group tolerance in the hydrogenation of aromatic and aliphatic nitro and nitrile compounds under 1 bar H2 and could be recycled and reused at least 10 times. By changing the reaction conditions of the hydrogenation of nitriles, symmetric or unsymmetric secondary amines were also afforded selectively. The experimental and computational studies suggested reversible nitrile coordination to nickel followed by 1,2-insertion of coordinated nitrile into the nickel-hydride bond occurring in the turnover-limiting step. In addition, DUT-5-NiH is also an active catalyst for chemoselective hydrogenolysis of carbon-oxygen bonds in aryl ethers to afford hydrocarbons under atmospheric hydrogen in the absence of any base, which is important for the generation of fuels from biomass. This work highlights the potential of MOF-based single-site earth-abundant metal catalysts for practical and eco-friendly production of chemical feedstocks and biofuels.
Discovery of Novel Substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide Analogues as Potent Human Adenovirus Inhibitors
Xu, Jimin,Berastegui-Cabrera, Judith,Ye, Na,Carretero-Ledesma, Marta,Pachón-Díaz, Jerónimo,Chen, Haiying,Pachón-Ibá?ez, Maria Eugenia,Sánchez-Céspedes, Javier,Zhou, Jia
, p. 12830 - 12852 (2020/11/13)
An effective therapy for human adenovirus (HAdV) infections in immunocompromised patients and healthy individuals with community-Acquired pneumonia remains an unmet medical need. We herein reported a series of novel substituted N-(4-Amino-2-chlorophenyl)-5-chloro-2-hydroxybenzamide analogues as potent HAdV inhibitors. Compounds 6, 15, 29, 40, 43, 46, 47, and 54 exhibited increased selectivity indexes (SI > 100) compared to the lead compound niclosamide, while maintaining sub-micromolar to low micromolar potency against HAdV. The preliminary mechanistic studies indicated that compounds 6 and 43 possibly target the HAdV DNA replication process, while compounds 46 and 47 suppress later steps of HAdV life cycle. Notably, among these derivatives, compound 15 showed improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreased cytotoxicity (CC50 = 156.8 μM), and low in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosamide, supporting its further in vivo efficacy studies for the treatment of HAdV infections.
